乐心医疗(300562) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was CNY 260,374,797.52, a decrease of 28.79% compared to CNY 365,624,197.46 in the same period last year[5] - Net profit attributable to shareholders was CNY 1,286,018.55, down 90.09% from CNY 12,978,298.10 year-on-year[5] - Total operating revenue for Q1 2022 was CNY 260.37 million, a decrease of 28.7% compared to CNY 365.62 million in the same period last year[25] - Total operating costs for Q1 2022 were CNY 268.60 million, down 25.2% from CNY 358.98 million year-over-year[25] - Net profit for Q1 2022 was CNY 1.11 million, a significant decline of 88.6% from CNY 9.71 million in Q1 2021[26] - The company reported a total comprehensive income of CNY 1.07 million for Q1 2022, compared to CNY 9.65 million in the same quarter last year[27] - Basic and diluted earnings per share for Q1 2022 were both CNY 0.01, down from CNY 0.07 in Q1 2021[27] Cash Flow - The net cash flow from operating activities increased significantly by 939.45%, reaching CNY 43,925,115.81, compared to a negative cash flow of CNY -5,232,595.94 in the previous year[14] - The net cash flow from operating activities for Q1 2022 was ¥43,925,115.81, a significant improvement compared to a net outflow of ¥5,232,595.94 in Q1 2021[30] - Total cash inflow from investment activities was ¥102,009,190.14, compared to ¥39,257,480.00 in the same period last year, resulting in a net cash flow from investment activities of ¥47,498,024.77, up from ¥14,096,783.38[30] - The net cash flow from financing activities was ¥2,266,206.31, a decrease from ¥370,393,135.70 in Q1 2021, primarily due to lower cash inflow from investment[31] - The total cash outflow for operating activities was ¥461,501,292.31, compared to ¥511,360,274.64 in Q1 2021, indicating improved cash management[30] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,636,175,441.87, down 8.82% from CNY 1,794,485,114.25 at the end of the previous year[5] - Total current liabilities decreased from ¥711,349,889.91 to ¥547,797,910.28, a reduction of about 22.9%[22] - Total liabilities amounted to CNY 581.85 million, a decrease from CNY 747.10 million year-over-year[26] - Total equity attributable to shareholders of the parent company was CNY 1,061.96 million, up from CNY 1,054.84 million in the previous year[26] Shareholder Information - Total number of common shareholders at the end of the reporting period is 22,530[16] - The largest shareholder, Pan Weichao, holds 37.54% of shares, totaling 80,602,574 shares, with 34,530,000 shares pledged[16] - The total number of shares held by the top ten unrestricted shareholders amounts to 37,150,000 shares[17] - The company has a total of 67,999,506 shares under lock-up due to executive restrictions[19] Government Support and Subsidies - The company received government subsidies amounting to CNY 1,275,779.04, contributing to other income of CNY 1,362,665.59, which increased by 319.78% year-on-year[13] Research and Development - Research and development expenses increased to CNY 33.01 million, up 14.0% from CNY 28.98 million in the previous year[26] Inventory and Accounts Receivable - The company experienced a 41.78% decrease in accounts receivable, totaling CNY 234,069,179.69, due to improved customer payment management[11] - Accounts receivable decreased significantly from ¥402,020,098.66 to ¥234,069,179.69, a reduction of about 41.8%[21] - The company reported a total of ¥200,454,047.96 in inventory at the end of the reporting period, down from ¥208,807,972.42[21] Production Costs and Profit Margins - The net profit margin was significantly impacted by increased production costs due to global supply chain issues and a strategic focus on core business areas[6]